Biotech Shares Higher Following Monkeypox Test Kit Annoucement

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, September 20, 2022

A London-based biotech company is seeing its shares soar on Tuesday after it was announced that the company has distributed a monkeypox-test kit in certain market. Having flashbacks of the beginning of the COVID-19 pandemic, naturally traders jumped on this trade immediately, sending share of Virax Biolabs Group Ltd (Nasdaq:VRAX) higher during Tuesday’s session.

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Traders were extremely optimistic about the news as shares reached up to $3.74/share (+51.42%) at the session high. This move is on extremely high volume, indicating a potential consensus was met by the investment community.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.